IFNA1 and systemic lupus erythematosus: Recombinant antibodies recognizing pDC receptors, such as BDCA2 or ILT7, could inhibit IFN production by pDCs or deplete pDCs, with promising results both in vitro and in vivo in SLE patients [74, 75, 226, 227].